Celgene's Pomalyst plus Velcade and dexamethasone meets in Phase III for MM

Celgene Corp. (NASDAQ:CELG) reported data from the open-label, international Phase III OPTIMISMM trial in about 559 patients with relapsed or refractory multiple myeloma (MM) who received prior treatment with Revlimid lenalidomide showing that Pomalyst pomalidomide (CC-4047) plus Velcade bortezomib and low-dose dexamethasone met the primary endpoint of improving progression-free survival (PFS) vs. Velcade plus low-dose dexamethasone.

Secondary endpoints in the trial include overall survival (OS), overall response rate (ORR), duration of response and safety...